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Abstract Ischemic stroke is a leading cause of disability
worldwide. In cerebral ischemia there is an enhanced expres-
sion of matrix metallo-proteinase-9 (MMP-9), which has been
associated with various complications including excitotoxicity,
neuronal damage, apoptosis, blood–brain barrier (BBB) open-
ing leading to cerebral edema, and hemorrhagic transformation.
Moreover, the tissue plasminogen activator (tPA), which is the
only US-FDA approved treatment of ischemic stroke, has a
brief 3 to 4 h time window and it has been proposed that
detrimental effects of tPA beyond the 3 h since the onset of
stroke are derived from its ability to activate MMP-9 that in
turn contributes to the breakdown of BBB. Therefore, the
available literature suggests that MMP-9 inhibition can be of
therapeutic importance in ischemic stroke. Hence, combination
therapies of MMP-9 inhibitor along with tPA can be beneficial
in ischemic stroke. In this review we will discuss the current
status of various strategies which have shown neuroprotection
and extension of thrombolytic window by directly or indirectly
inhibiting MMP-9 activity. In the introductory part of the
review, we briefly provide an overview on ischemic stroke,
commonly used models of ischemic stroke and a role of MMP-
9 in ischemia. In next part, the literature is organized as various
approaches which have proven neuroprotective effects through
direct or indirect decrease in MMP-9 activity, namely, using
biotherapeutics, involving MMP-9 gene inhibition using viral
vectors; using endogenous inhibitor of MMP-9, repurposing of
old drugs such as minocycline, new chemical entities like DP-
b99, and finally other approaches like therapeutic hypothermia.
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TIMP-1 Tissue Inhibitor of Matrix Metalloproteinases-1
tPA tissue-type plasminogen activator
BBB Blood Brain Barrier
Introduction
Ischemic Stroke
Causes, Classification, and Management
Worldwide, stroke is among the leading causes of death and
serious disability [1]. In stroke, there is a disruption in the
blood supply to the brain leading to rapid loss of brain func-
tion. As a result, the affected area of the brain cannot function,
which might result in an inability to move one or more limbs
on one side of the body, inability to understand or speak, or to
see one side of the visual field.
Strokes are classified as ischemic and hemorrhagic.
Ischemic strokes are caused by obstruction of the blood sup-
ply, while hemorrhagic strokes results from rupture of a blood
vessel. Most of the strokes (about 85–90 %) are ischemic.
Occasionally, hemorrhagic strokes develop in ischemic brain,
and called as hemorrhagic transformation of ischemic stroke,
although it is unknown how many hemorrhages actually start
off as ischemic stroke.
Currently, there is only one US-FDA approved treatment
for ischemic stroke, i.e., tissue-type plasminogen activator
(tPA). To be effective, tPAmust be administered intravenously
within the first 3–4 h of the event due to risks of hemorrhagic
transformation of ischemic stroke [2–4]. Because of narrow
time window, only a few percent of patients qualify for this
treatment. Hence there is a need to find new therapeutic targets
for increasing the therapeutic time window of tPA and protect
neurons from ischemic injury.
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Models for Ischemic Stroke
To test potential therapeutic interventions and to understand
underlying mechanisms in ischemic stroke there are several
in vitro and in vivo models available in different species.
Therefore, depending on the research questions a specific
model is chosen. In this section, we will give a brief outline
of the most commonly used models of ischemic stroke rather
than their precise methodology, which is beyond the scope of
this review and has been described in detail by others [5–8].
In Vitro Models There are several in vitro models available for
ischemic stroke, but the most established and widely used
in vitro model for ischemia is oxygen glucose deprivation
(OGD). In this model primary neuronal cultures, organotypic
cultures, and acute brain slices can be incubated in deoxygen-
ated, glucose-free medium to mimic the interruption of the
supply of oxygen and nutrients to the brain parenchyma [9].
An alternative to OGD is chemical ischemia model, which
can simulate certain aspects of ischemic brain injury. In this
model, sodium azide or sodium cyanide, inhibitors of oxida-
tive metabolism, often together with 2-deoxyglucose, an
inhibitor of glycolysis, are used to induce hypoxia and hypo-
glycemia in cultures [10].
In Vivo Models Rodents are the most commonly used animals
for ischemic stroke model because of a resemblance to
humans in their cerebral anatomy and physiology, small size,
and low cost. There are varieties of rat and mouse models
available for cerebral ischemia; see reviews [5, 7, 8, 11]. The
most basic models of mimicking complete global brain
ischemia are: decapitation, aorta/vena cava occlusion by co-
agulation of both vertebral arteries, followed by the transient
occlusion of both common carotid arteries (four-vessel occlu-
sion); external neck tourniquet or cuff and cardiac arrest. For
incomplete global ischemia, the most commonly used model
is hypoxic ischemia. In this model there is permanent unilat-
eral carotid artery ligation with a subsequent 3-h exposure to a
hypoxic environment (8 % oxygen) that creates a unilateral
infarct in the hemisphere ipsilateral to the ligation. The area of
injury is typically concentrated in periventricular regions of
the brain, especially cortical and hippocampal regions [12].
Experimental focal cerebral ischemia is the most powerful
model of ischemic stroke because it closely mimic the changes
that occur during and after human ischemic stroke; see review
[13]. There are various approaches for inducing focal cerebral
ischemia, for instance thromboembolic stroke is produced by
blood clot formation. This model is of great interest because it
is closest in resemblance to human ischemic stroke and its
utility in evaluating thrombolytic therapies. Another model
called photo-thrombotic stroke is a way of inducing thrombo-
sis by systemic injection of a photoactive dye in combination
with illumination by a light beam transmitted through the
intact skull. The illumination of photo dye causes alteration
in dye which leads to oxidative damage to the endothelium
leading to platelet aggregation. Microsphere embolization is
another model, with the severity of ischemic damage related to
the number of emboli used. Middle cerebral artery occlusion
(MCAO) is surgical occlusion using a filament.
It shall, however, be stressed that since human stroke
comes in many forms, no single animal model is able to
encompass all of the variables known to affect human ische-
mic stroke. Thus none of the available models perfectly sim-
ulates human stroke which makes it very difficult to interpret
the results in context of human stroke. Hence, this is one of the
main reasons of many drugs failing in clinical trials, because
of poor translation of preclinical data to clinical stage.
Therefore, preclinical data from animal models should be very
cautiously interpreted before extrapolating to humans.
Pathological Assessment of Brain Damage in Ischemic
Models
For assessing neuronal damage in in vitro models, propidium
iodide is most commonly used. It is a marker for dead or dying
cells, as it only enters and stains cell nuclei after loss of cell
membrane integrity. Other colorimetric assays for assessing
cytotoxicity after ischemia include, 3-(4, 5-dimethyl-2-
thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay
and lactate dehydrogenase (LDH) assay. MTT is reduced by
metabolically active cells to insoluble purple formazan dye
crystals which can be visualized by colorimetry. While LDH is
an enzyme which converts pyruvic acid to lactic acid and it can
be readily detected when cell membranes are no longer intact.
The effectiveness of in vivo models can be estimated by
measuring tissue loss and functional deficits. Infarct volume is
one of the major criteria which is traditionally measured
by quantitative histology. For infarct size measurement,
tripenthyltetrazolium chloride (TTC) and hematoxylin–eosin
(H&E) staining is most commonly used. TTC is a redox
indicator which indicates cellular respiration. After TTC stain-
ing the areas of potential damage after ischemic stroke are
paler as compared to healthy viable tissue, which will stain
deep red after stroke.
Blood brain barrier (BBB) integrity is another important
parameter which is most commonly assessed by Evans blue
test. Evans blue is a marker of BBB permeability for albumin.
There are also various other ways for measuring BBB perme-
ability and one of the most common method after Evans blue
test is by observing immunolocalization of IgG. It has been
shown that there is increased permeability to endogenous
proteins such as IgG when BBB is compromised and hence
this property of IgG is capitalized to measure BBB integrity.
Further, immuno-cyto/histo-chemistry for tight junction pro-
tein such as ZO-1, occludin, and claudin-5 is also a good
indicator of BBB integrity.
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Apart from these morphological parameters, neurological
assessments are very useful but these deficits are most difficult
to assess in animals. Usually, motor deficits are quantified by
using sensorimotor tests including rotarod, grid walking, limb
placing, beam walking, and sticky label test [13].
MMP-9 and Its Role in Ischemia
Physiological and Pathological Significance of MMP-9
Matrix metalloproteinases (MMPs) form a mutligene family
of zinc-dependent endopeptidases of over 25 enzymes, mostly
secreted and acting outside the cells. Their targets include
other proteinases, proteinase inhibitors, clotting factors, che-
motactic molecules, latent growth factors, growth factor-
binding proteins, cell surface receptors, cell–cell adhesion
molecules, and virtually all structural extra-cellular matrix
proteins. Thus MMPs are able to regulate many biologic
processes [14].
In particular, MMP-9 (gelatinase B, 92 kDa type IV collage-
nase) is produced in a latent form in the cell and after release to
extracellular space, it is activated by cleavage off the propeptide
[15]. It is involved in the breakdown of extracellular matrix in
various physiological processes, such as embryonic develop-
ment, reproduction, angiogenesis, bone development, wound
healing, cell migration, and recently, it has been shown to be
increasingly important in several aspects of central nervous sys-
tem activity including its role in learning and memory [16, 17].
Enhanced expression and activities of MMPs especially
MMP-9 have been observed under numerous pathologic con-
ditions [16, 18], including many neuropsychiatric disorders
[19] such as epilepsy, autism spectrum disorders, addiction,
and bipolar disorders and schizophrenia. It has also been
implicated in other CNS disorders such as Alzheimer’s dis-
ease, multiple sclerosis, brain tumors, Guillain-Barre syn-
drome, spinal cord injury, ischemic stroke, and excitotoxic/
neuroinflammatory processes [16, 20].
Current Techniques for Assessing MMP-9 Activity
For assessing MMP-9 activity, the most commonly used tech-
nique is zymography and reverse zymography for assessing
activity of its inhibitors. There are variations of this method
such as in situ zymography and real-time zymography.
Standard MMP-9 zymography is a variation on acrylamide
gel electrophoresis. The gel used for zymography, commonly
referred to as zymogram, contains gelatin (substrate of MMP-
9) incorporated directly into the gel during polymerization.
Following electrophoresis of the sample containing MMP-9
(gelatinase B), SDS is removed from the gel by exchange with
Triton X-100. This allows the gelatinases in the sample to
renature and auto-activate, following incubation of gels in
activation buffer. MMP-9 activity is revealed by coomassie
blue staining. A variation of standard zymography called as
real-time zymography in which fluorescently tagged (FITC-
tagged) gelatin which allows real-time monitoring of activity
under UV light and no coomassie blue staining is needed.
For assessing MMP-9 activity in histological sections in situ
zymography is used. In this method frozen sections are placed
on glass slides coated with fluorescently labeled matrix proteins.
After incubationMMP activity can be observed as black patches
in the fluorescent background due to proteolysis of the matrix
protein [21]. In another variation, frozen sections are incubated
with dye-quenched (DQ) gelatin which upon proteolysis by
MMP-9 becomes fluorescent. Hence, the MMP-9 activity can
be visualized in high resolution as bright fluorescence spots [22].
Another method for measuringMMP-9 activity is gelatinase
assay. In this method DQ gelatin is used as a substrate for
MMP-9. As DQ gelatin is cleaved by MMP-9, it has fluores-
cence which can be quantified by microplate reader.
Increase in MMP-9 Activity After Cerebral Ischemia
During the last decade, a vast clinical data have been accumu-
lated from many studies which confirm critical role of MMP-9
and its deleterious effects during human stroke and reperfusion
injury [23–27]. These results have also been correlated in
number of animal models, which have shown a marked in-
crease of MMP-9 expression in ischemic stroke [28–32].
MMP-9 might be released in response to ischemic insult
from neurons, oligodendroglia, reactive astrocytes, and activat-
ed microglia [33]; furthermore, free radicals, tPA, and other
molecules which are released after ischemic insult have the
capacity to activateMMP-9; see reviews [34, 35]. This increase
in MMP-9 is further associated with various complication
including excitotoxicity, neuronal damage [36], apoptosis [37,
38], oxidative stress [39], interference with oxidative DNA
repair mechanisms [40], and most importantly BBB opening
leading to cerebral edema and hemorrhagic transformation [41]
after cerebral ischemia. Moreover, it has been proposed that
detrimental effects of tPA beyond the 3 h of stroke onset are
derived from tPA’s ability to activate MMP-9 [42–44]. This in
turn contributes to the breakdown of BBB [44–47].
The first study showing increase ofMMP-9 in human brain
after ischemia was probably done by Clark et al. [48]. They
showed that MMP-9 activity was markedly elevated in the
infarcted human cerebral tissue after 2 days post-infarction as
compared to non-infarcted tissue. This was followed by Heo
et al. who showed, using gelatin zymography that after
MCAO in non-human primates, only MMP-9 increases tran-
siently after 2 h of stroke onset not MMP-2 [49] Fig. 1. They
showed that MMP-9 expression only was significantly in-
creased in subjects with hemorrhagic transformation and not
any other MMP. These results were corroborated in many
other stroke models also, such as mouse model of focal
cerebral ischemia, where it has been shown that MMP-9 is
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increased after onset of stroke and further these increase
correlates with increase in BBB permeability which was de-
termined by Evans blue test [50, 51]. Similarly, there are
multiple data from other animal models of ischemia, which
suggest increase in MMP-9 relating to hemorrhagic transfor-
mation [52]. Furthermore, recent data confirm the presence of
high MMP-9 levels not only in infarct tissue but also in the
peri-infarct areas, suggesting that MMP-9 involvement in the
process of infarct size growth [53–55]. Therefore, it has been
suggested that MMP-9 can be considered as possible marker
for brain ischemia, as well as a predictor of hemorrhage in
patients treated with tPA [56].
These results have collectively showed excessive activation
of MMP-9 has deleterious effects to the brain, which are
associated with BBB leakage and inflammation. Thus, inhibi-
tion of MMP-9 is considered as a potential therapeutic target.
MMP-9 Transgenic and Knock Out in Ischemic Stroke
The first study onMMP-9 knock out (KO) mice was from Lo’s
group in traumatic brain injury model which showed that
MMP-9 KO mice have less motor deficits than wild-type
(WT) mice [57]. In focal cerebral ischemia model MMP-9
KO mice have shown significant BBB protection. The BBB
integrity by Evans Blue test has been shown to be significantly
attenuated in MMP-9 KO mice as compared with WT [58].
Furthermore, in white matter, degradation of the MMP-9 pos-
sible substrate myelin basic protein was also significantly re-
duced in KO mice as compared with WT [58]. Another study
on cerebral hypoxic–ischemia model in immature brain on
post-natal 9-day-old mice demonstrated that MMP-9 KOs are
protected from ischemic damage [59]. Apart fromMMP-9 KO
mice, recently, CEACAM-1 (carcino-embryonic antigen-
related cell adhesion molecule-1) KO mice, has also been
shown to protect BBB breakdown, after tMCAO in mouse;
through MMP-9-inhibition-mediated pathway [60]. Taken
together, it has been shown by different ischemia models that
MMP-9 KO mice (and also others KO such as CEACAM1
KO) have reduced ischemic brain damage.
TIMP-1 Transgenic and KO in Ischemic Stroke
Tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) is
known to bind MMP-9 with high affinity and to block its
enzymatic function. TIMP-1 is upregulated following an
excitotoxic injury, which has been hypothesized to be part of
a general neuronal response that possibly mediates tissue
reorganization and/or neuroprotection [61]. Being endoge-
nous inhibitor of MMP-9 it is suggested that TIMP-1 can play
a neuroprotective role in cerebral ischemia. Therefore to
Fig. 1 Obstruction of blood supply causes ischemic injury which in turn
causes activation of various factors includingMMP-9, which is suggested
to be involved in excitotoxicity, neuronal damage and BBB opening.
Reperfusion, using tPA, causes further activation of MMP-9 which has
been shown to be involved in hemorrhagic transformation of ischemic
stroke and also responsible for brief therapeutic window of tPA. There-
fore, it has been proposed that combination therapy of MMP-9 inhibitor
with tPA can be neuroprotective. In this review, we discuss various
approaches of MMP-9 inhibition which have shown to be therapeutically
beneficial
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evaluate neuroprotection by genetic inhibition of MMP-9
there were various studies using TIMP-1 transgenic mice.
It has been shown that in TIMP-1 overexpressing transgenic
mice after 2 h of transient focal cerebral ischemia, MMP-9 levels
were lower as compared with WT [62]. Correspondingly, BBB
leakage is also ameliorated by TIMP-1 overexpression, and after
24 h infarction volumes they have reduced. On the other hand, in
TIMP-1 KO mice, MMP-9 protein expression and gelatinolytic
activity were significantly more augmented after cerebral ische-
mia than those in WT mice. This MMP-9 activity was also
accompanied by exacerbated BBB disruption, neuronal apopto-
sis, and ischemic injury [63]. Taken together, TIMP-1 transgenic
andKOmice provide a first proof-of-principle that geneticMMP-
9 inhibition may be neuroprotective after ischemic brain injury.
In the next section, we will discuss the current status of
various pharmacological approaches for protecting ischemic
brain from deleterious effects of MMP-9. There have been
attempts by using endogenous and chemical MMP-9 inhibi-
tors in combination with tPA to protect the ischemic brain and
further increasing thrombolytic window of tPA.
Therapeutics Approaches of MMP-9 Inhibitions
During the last two decades, a great deal of attention has been
focused on neuroprotective therapies [64]. MMP-9 has been
identified as aberrantly overactive in ischemia, potentially caus-
ing deleterious effects during ischemia and after reperfusion, and
hence its inhibition has been considered as a potential therapeutic
target [65]. The idea of neuroprotection by inhibiting MMP-9 in
ischemic stroke is not very old, but multiple studies have been
done during the last decade using various strategies for MMP-9
inhibition. In a number of in vitro and in vivo models, MMP-9
inhibition has shown to be neuroprotective, e.g., by using
lentiviral-mediated MMP-9 gene silencing [66] or by delivering
recombinant TIMP-1 in native form [67, 68] or by PLGA
nanoparticles [69]. Notably, minocycline appears to be the most
studied drug for ischemic stroke.
Biotherapeutics
Biotherapeutics are biological materials such as recombinant
proteins, monoclonal antibodies, and siRNAs used to encom-
pass therapeutics effects. Several biotherapeutic approaches
are being used to inhibit MMP-9, such asMMP-9 neutralizing
antibodies, MMP-9 siRNA, or shRNA delivered through ad-
enoviral vectors, lentiviral vectors, quantum dots, and gold
nanoparticles, which all have ameliorated deleterious
consequences of ischemic stroke. Furthermore, there
have been studies of inhibiting MMP-9 activity by admin-
istering MMP-9 neutralizing monoclonal antibody even after
focal ischemic insult that have shown to decrease the infarct
size [70].
MMP-9 Gene Silencing
Various studies on focal cerebral ischemic models by MMP-9
gene silencing through adenoviral and lentiviral vectors have
shown neuroprotective effects. There was significant reduc-
tion in brain infarction volume, brain water content, and
neurobehavioral deficits following lentiviral-delivery-
mediated MMP-9 silencing by LV-mmp9shRNA treatment
[66]. Additionally, Evan’s blue and IgG extravasation were
reduced showing BBB integrity. Another study, showing ther-
apeutic application of MMP-9 gene silencing by intracerebro-
ventricular injection of liposomal formulation containing
MMP-9 siRNA within 60 min after 2 h of a middle cerebral
artery occlusion-induced focal ischemia rat model showed
BBB protection [71]. These findings provide evidence that a
liposomal formulation of siRNA might be used in vivo to
silence the MMP-9 gene and could potentially serve as an
important therapeutic alternative in patients with cerebral
ischemia.
Also, there have been novel strategies of MMP-9 gene
silencing such as by gold nano rods (GNRs), which can
electrostatically bind with MMP-9 siRNA to form a nano
complex (called as nanoplex). This nanoplex can be readily
up taken by brain microvascular endothelial cells (BMVECs)
that constitute the BBB. It has been shown that silencing of
MMP-9 gene expression by this GNR nanoplex in BMVEC
increases the expression of tight junction proteins namely ZO-
1, Occludin, and Claudin-5 thereby decreasing endothelial
permeability [72].
There are other novel studies involving application of a
nanoparticle-based siRNA delivery system, such as nanoplex
of quantum dot (QD) and MMP-9-siRNA, which has been
shown to silence MMP-9 gene expression in BMVECs and
other cells, e.g., leukocytes [73]. Their study showed that this
QD nanoplex downregulated the expression of MMP-9 gene
in BMVEC and prevented breakdown of the BBB and thus
inhibited subsequent invasion of the CNS by infected and
inflammatory cells. The results also showed that silencing of
MMP-9 gene expression resulted in the upregulation of such
ECM proteins as collagen I, IV, V, and a decrease in endothe-
lial permeability, which was measured by trans-endothelial
resistance across the BBB in the in vitro BBB model.
Furthermore, they have shown that MMP-9 gene silencing
results in an increase in expression of the gene TIMP-1
which strengthen the hypothesis of TIMP-1’s role in
neuroprotection.
TIMP-1 as Therapeutic Strategy
In aggregate, the literature indicates the importance of a bal-
ance between the levels of MMP-9 and its natural inhibitor
TIMP-1 in maintaining the basement membrane integrity in
ischemic stroke, as proteolysis of MMP-9 is tightly controlled
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by TIMP-1. Therefore, TIMP-1 is considered as a therapeutic
strategy for ameliorating deleterious effects of MMP-9 in
ischemic stroke.
Notably, it has been demonstrated earlier that within hours
of applying recombinant TIMP-1 either in native form or
through adenoviral-mediated gene transfer to organotypic
hippocampal cultures, neurons are highly protected against
excitotoxic injury induced by kainic acid [68].
In vivo delivery of TIMP-1 by using adenoviral vectors
[74] has been shown to significantly reduce neuronal damage
(by approximately 50 %) after TIMP-1 gene transfer, as com-
pared to control. The only main obstacle of using TIMP-1 as a
therapeutic agent is it has short half-life in vivo [75, 76],
therefore, there have been attempts to extend its bioavailabil-
ity such as PEGylating the TIMP-1 [76], so in future it can be
developed as a neuroprotective. Furthermore, TIMP-1 being
large protein cannot cross the BBB. Therefore, to enhance it
BBB penetration and increase its circulation time, TIMP-1-
loaded PLGA nanoparticles have been formulated [69]. These
nanoparticles have shown in vitro neuroprotection-mediated
MMP-9 inhibition [69]. It is suggested that neuroprotective
effects of TIMP-1may arise not only due toMMP-9 inhibition
but also in combination of several other mechanisms, such as
eythropoietin-induced neuroprotection as shown in oxygen
glucose deprivation model by [67].
Re-purposing Old Drugs
As drug pipeline of pharmaceutical industries are drying up,
the drug repositioning or repurposing has thus grown into
importance during the last decade [77, 78]. The tetracycline
derivative, minocycline which is a broad-spectrum antibiotic
is the most studied drug for its neuroprotective function in
ischemic stroke. Remarkably, all studies have shown the
decrease in MMP-9 activity after minocycline treatment and
subsequent neuroprotection. There are a few reasons why
minocycline is chosen a lead molecule for exploring its
neuroprotective effects. First, it has proven safety record over
decades as an antibiotic. Secondly, it has very good ability to
diffuse into the central nervous system at clinically effective
levels. And finally, aside from its antimicrobial properties,
minocycline has been found to have inhibitory effects on
matrix metalloproteinases [79, 80]. This suggests that it may
have potential for development into an effective treatment for
ischemic stroke [81–83]. Concordantly, minocycline has been
found to have neuroprotective effects in animal models of a
number of diseases including stroke [84].
There are many pieces of evidence derived from in vitro
and in vivo studies that neuroprotection mediated by
minocycline is through MMP-9 inhibition. In vitro it has been
shown that minocycline ameliorates oxygen-glucose
deprivation-induced cell cytotoxicity and down-regulate the
production and activity of matrix metalloproteinase-9 [85]. In
vivo it has been shown that minocycline inhibits enzymatic
activity of gelatin proteases activated by ischemia after exper-
imental stroke and is likely to be selective for MMP-9 at low
doses [81]. Furthermore, in vivo studies have shown that the
neuroprotective effects of minocycline may be mediated by
interfering with MMPs. Koistinaho et al. has compared
minocycline’s protective effect in WT and MMP-9 KO mice
[86]. They showed that minocycline inhibited ischemia-
provoked pro-MMP-9 induction in WT mice, but was not
protective in MMP-9 KO mice.
Combinational therapy of minocycline with tPA has shown
to extend the 3 h window to 6 h in embolic focal ischemia
model in rat [87]. Such treatment results also in a decrease of
MMP-9 plasma levels, reduced infarction, and ameliorated
brain hemorrhage. Moreover, the exploratory clinical trials
of minocycline have shown to improve neurological outcome
in stroke and it was found that it lowers plasma matrix
metalloproteinase-9 in tPA-treated subjects [88]. In the future,
combining minocycline with tPA may prevent the adverse
consequences of thrombolytic therapy through suppression
of matrix metalloproteinase-9 activity [89].
Another class of drug, Statins which are 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors, have shown
pleiotropic effects and are considered as potential neuroprotective
agents in the treatment of stroke. Atorvastatin which is a member
of statin family and notably marketed by Pfizer as a calcium salt
under the trade name “Lipitor” which is the highest selling
drug, used for lowering blood cholesterol and hence it has
well-proven safety record. Atorvastatin has also been studied
for extending thrombolytic window of tPA [90]. In rats after
embolic middle cerebral artery occlusion, combination of
atorvastatin and tPA have been shown to extended the thera-
peutic window for stroke to 6 h without increasing the inci-
dence of hemorrhagic transformation. Furthermore, this com-
bination therapy also abolished tPA-induced upregulation of
MMP-9, as well as the degradation of collagen IV, leading to a
reduction in the incidence of hemorrhagic transformation
(10 %) as compared with the incidence during monotherapy
of the tPA group (40 %).
Recently, melatonin, which is a highly potent free radical
scavenger, has been shown to have neuroprotective effects by
reducing the elevated matrix metalloproteinase-9 level in a rat
photothrombotic stroke model. These findings suggest that
oxidative stress by free radicals might be highly associated
with the activation of the MMP-9 pathway and that melatonin
might protect against BBB disruption by reducing MMP-9
activity after cerebral ischemia through the reduction of oxi-
dative stress by scavenging free oxygen radicals [91]. Another
molecule, a lipoxin A(4) analog LXA(4) methyl ester
(LXA(4)ME), also prevents BBB dysfunction in a rat model
of focal cerebral ischemia reperfusion injury [92]. Its effects
are attributed to reduction in MMP-9 activity which is medi-
ated by increase in TIMP-1 expression.
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Hematopoietic growth factors such as erythropoietin (EPO)
provides neuroprotection and promotes neurogenesis and an-
giogenesis after stroke, similarly thrombopoietin (TPO), which
has significant homology with EPO (23 %) at the amino-acid
level and with neurotrophins (e.g., the highest homology with
BDNF, 36 %) in the N terminal region has shown efficacy in
reducing ischemic brain injury in MCAO model [93]. It pro-
tects the brain from the early, negative effects on the BBB and
improving functional outcome, partly by inhibiting the stroke-
induced increase in MMP-9. Angiotensin type 1 receptor
blocker such as olmesartan can reduce the reactive upregulation
in brain angiotensin II, MMP-2, MMP-9, and membrane type
1-MMP in the ischemic area to improve stroke index score,
infarct volume, and cerebral edema in cerebral ischemia model
[94]. Non-steroidal anti-inflammatory drugs such as indometh-
acin inhibitor of COX-1 and COX-2 has shown to significantly
reduce the expression and activity of MMP-9 as assessed by
immunoblotting and gelatin–substrate zymography and attenu-
ated the brain edema [95].
New Chemical Entities
DP-b99 is a new chemical entity that is discovered and devel-
oped by D-Pharm’s proprietary Membrane Active Chelators
(MAC) platform technology. DP-b99 has been shown to atten-
uate detrimental zinc-dependent membrane-associated process-
es, such as calpain activation and tumor necrosis factor-α-
induced activation of matrix metalloproteinase-9 [96].
Another MMP inhibitor KB-R7785 showed protective
effects against brain infarct formation in focal cerebral
ischemia [97].
Another new molecule SB-3CT, which is presented as a
highly selective inhibitor that is known to target MMP-9, has
protected neurons from apoptosis in transient focal cerebral
ischemia [98]. While on the other hand another study done on
immature brain (21 old postnatal Wistar rats) showed that
despite of significantly inhibiting MMP-9 activity after uni-
lateral carotid artery occlusion unilateral carotid artery occlu-
sion followed by exposure to hypoxia (8 % oxygen for 1 h),
SB-3CT failed to confer significant neuroprotection in [99].
Hence, further investigations are still needed by using other
recently reported selective water-soluble version of SB-3CT
or another MMP-9 selective inhibitor to resolve the role of
MMP-9 in the etiology of ischemic injury.
Miscellaneous
From the available data, it is clear that ischemic injury involves
numerous pathways via which cerebral hence the therapeutic
should be developed with the capacity to inhibit multiple
mechanisms simultaneously to provide synergistic beneficial
clinical effects for stroke patients. Therapeutic hypothermia is
among the most promising technique as a post-ischemic
pharmacological interventions and has been shown to provide
long-lasting neuroprotection in preclinical studies [100, 101].
It has been shown that therapeutic hypothermia also decreases
MMP-9 activity in rat after MCAO [102]. Moreover, combi-
nation of minocycline and hypothermia has shown to have
additional neuroprotection with decrease in MMP-9 activity
[103]. There have been important preclinical data suggesting
that moderate hypothermia significantly decreases MMP-9
activity and hence protect the ischemic brain [104, 105].
Recently, Zhao and colleagues have shown that focal mild
hypothermia (for 6 h, 33°C) can decrease expression of
MMP-9 and TIMP-1, resulting in improved neurological
function [106]. Furthermore, in humans after acute ischemic
stroke within 12 h of stroke onset when the patients were
treated with moderate hypothermia, i.e., patients were kept at
33°C body-core temperature for 48 to 72 h. It has been shown
that MMP-9 levels are significantly lower in patients treated
with moderate hypothermia as compared to the patients treated
with tPA [25]. And conversely, laminin levels are significantly
lower after tPA treatment as compared to hypothermia-treated
patients, suggesting lowering of MMP-9 activity after hypo-
thermia treatment. Therapeutic hypothermia has been investi-
gated in clinical trials and despite a reasonable amount of
clinical data still additional trials are needed to define the
optimal time window, temperature regimen, and precise
clinical indications for induction of therapeutic hypothermia
in the setting of acute stroke [107].
There are various other approaches which do not directly
inhibits MMP-9 but it has been shown that they do decrease
MMP-9 activity significantly. For e.g. platinum nanoparticles
as a novel reactive oxygen species scavenger were used after
MCAO and examined for their neuroprotective effects. The
study demonstrated that nanoparticles treatment ameliorates
neurological function and brain damage in acute cerebral
infarction with neuroprotective effect and most importantly
the nanoparticles also reduced MMP-9 activity [108].
Summary and Prospects
To conclude, accumulating data suggest that MMP-9 concen-
tration is significantly increased in both animal models of
cerebral ischemia and in human stroke. This increased
MMP-9 level is associated with neuronal damage, apoptosis,
BBB opening followed by cerebral edema, hemorrhagic trans-
formation, and reperfusion injury. ThereforeMMP-9 is among
the most important therapeutic targets in ischemic stroke. We
suggest that, as MMP-9 structure and its regulations at gene
level and protein level have been known, therefore, com-
pounds which can directly inhibit its activity or decrease
MMP-9 expression by blocking signal pathways should be
exploited for developing new therapeutics. Further, the en-
dogenous inhibitors of MMP-9, i.e., TIMP-1 should also be
Mol Neurobiol (2014) 49:563–573 569
explored for its possible beneficial effects. In future, combi-
nation therapies of tPA with MMP-9 inhibitor may be useful
for decreasing the risk and severity of thrombolytic therapy for
human stroke.
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